Corticosteroids have been reliable workhorses for managing inflammatory skin conditions. But they come with a ceiling—namely, long-term safety concerns and limited efficacy in achieving true, lasting repigmentation.

‍

A revolution is underway in how to approach complex dermatoses. The Janus kinase (JAK) pathway has emerged as a key player in the pathogenesis of many different pigment disorders and inflammatory conditions. JAK inhibitors are stepping in where steroids used to be the only option.

‍

In this Next Steps in Derm video interview, conducted in conjunction with the Pigmentary Disorders Exchange Symposium, San Diego dermatologist Neal Bhatia, MD, FAAD, shares why JAK inhibitors are a game-changer for treating pigmentary conditions. He outlines the safety profile and why that should give dermatology clinicians confidence in prescribing. Dr. Bhatia also addresses effective pathways targeted by JAK inhibitors and how JAK inhibitors impact repigmentation.

‍

When integrating JAK inhibitors into treatment protocols, Dr. Bhatia says counseling patients on timelines is key. While using JAK inhibitors for eczema is a sprint—often stopping the itch in its tracks with noticeable results in just two days—treating vitiligo is a marathon. Ultimately, patience is required for both the clinician and the patient to see long-term improvements.